Graham works across a diverse range of biotechnology and life sciences subject matter, particularly focusing on immunology. Graham's areas of technical speciality include allergy and autoimmunity, with extensive patent drafting and prosecution experience in the fields of peptide immunotherapy, antibodies and related immunomodulatory agents, and genomics.
He has recently relocated to lead J A Kemp's Paris office. For more information click here.
He spends much of his time handling European, British and foreign patent applications for a range of clients, particularly in the UK and Scandinavia. Graham has also acted in European Patent Office (EPO) oppositions relating particularly to antibody technology and production of pharmaceutically active compounds in plant cells, and has attended multiple oral proceedings at Opposition Division and Board of Appeal level at the EPO.
Since a two-year period earlier in his career when he spent time each week on secondment there, Graham has been heavily involved in advising Circassia, at that time a startup. Circassia are now a publicly traded company following an IPO whose success was assisted by the IP portfolio JA Kemp had helped the business to develop. As a result, Graham not only has experience of global patent portfolio management but also a good understanding of the IP needs of such businesses from the inside, including due diligence and freedom to operate issues.
As part of the firm's SPC team, Graham also has experience with filing and advising on Supplementary Protection Certificates and related regulatory issues, in particular for biopharmaceuticals and antibodies. Graham is "recommended" in The Legal 500 and the MIP IP Stars Handbook.
Graham joined J A Kemp in 2005 and became a partner in 2015.
University of Oxford, Masters Degree in Molecular and Cellular Biochemistry; University of Oxford, DPhil in Immunology
European Patent Attorney, UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA), Member of the Institute of Professional Representatives before the European Patent Office (EPI)